Welcome to our dedicated page for Dariohealth news (Ticker: DRIO), a resource for investors and traders seeking the latest updates and insights on Dariohealth stock.
DarioHealth Corp. develops digital health and digital therapeutics solutions for people managing chronic conditions. The company’s multi-condition platform uses data analytics, connected health devices, personalized interventions and one-on-one coaching across diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
DRIO news commonly covers quarterly financial results, conference calls, commercial activity with health plans, payers, self-insured employers, care providers and consumers, and clinical research based on real-world platform data. Other recurring updates include AI-enabled product development such as DarioIQ, evidence publications, board and governance changes, and capital or credit arrangements supporting the company’s digital health business.
DarioHealth Corp. (Nasdaq: DRIO) announced a study published in the Journal of Medical Internet Research highlighting the effectiveness of its integrated digital therapeutics platform in managing both diabetes and hypertension. The study revealed that users managing both conditions saw a significant reduction in average blood glucose and blood pressure levels, with 27% achieving more than a 10mmHg systolic blood pressure reduction. Dario emphasizes the importance of a holistic approach to chronic condition management and aims to lead in integrated health solutions.
Summary not available.
DarioHealth Corp. (Nasdaq: DRIO) announced an agreement to acquire assets from Physimax Technologies Ltd., specializing in computer vision technology for musculoskeletal screening. This technology, used by organizations like the NBA and U.S. military, offers automated injury assessments and personalized training programs. The acquisition involves issuing up to 256,660 shares and a cash payment of $500,000, alongside assuming liabilities of approximately $1,020,000. DarioHealth aims to enhance its offerings, promoting growth in musculoskeletal health care while reducing reliance on human support.
DarioHealth Corp. (NASDAQ-CM: DRIO) announced a contract with a large regional health plan to provide its digital therapeutic solution for diabetes to eligible Medicaid members in the mid-Atlantic region. Expected to contribute to revenue in Q2 2022, this partnership aims to improve access to innovative diabetes care and reduce medical costs for Medicaid participants, who face significantly higher healthcare expenses. DarioHealth’s digital therapeutics platform addresses various chronic conditions, emphasizing personalized experiences and behavior change for better health outcomes.
DarioHealth Corp. (Nasdaq: DRIO) is set to host an investor webinar on January 19, 2022, at 8 am ET, focusing on emerging digital health trends. The event will feature insights from industry experts Sari Kaganoff and David Kaplan, along with DarioHealth executives detailing the company's digital therapeutics platform and 2021 achievements. DarioHealth aims to transform healthcare with its AI-powered platform addressing chronic conditions like diabetes and hypertension. To register, visit their website.
Summary not available.
DarioHealth Corp. (Nasdaq: DRIO) announced a strategic partnership with a leading employer benefits brokerage to provide its digital therapeutic solutions for diabetes, hypertension, and musculoskeletal health. This new employee health benefits product will be available to over 2,300 small business clients starting early 2022. DarioHealth was selected for its proven engagement and cost-effective clinical results, positioning it as the exclusive chronic condition management solution in the benefits package, potentially benefiting millions of small business employees.
Summary not available.
Summary not available.
DarioHealth Corp. (Nasdaq: DRIO) announced its Q3 2021 financial results, showcasing a remarkable 176% revenue growth year-over-year, reaching $5.6 million. Pro-forma gross margin improved to 45% from 26.9% a year prior. Despite robust revenue growth, the company reported an operating loss of $22.5 million, up 240.8% from Q3 2020. Dario secured 47 contracts to date, with a billion-dollar pipeline, primarily focused on multi-condition digital health solutions. The firm is well-funded with $51.3 million in cash, supporting its growth strategy in the competitive digital therapeutics market.